Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune Inc
(NQ:
ALT
)
8.680
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via
MarketBeat
Exposures
Product Safety
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
July 01, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
June 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Altimmune
June 21, 2024
Via
Benzinga
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
June 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
Via
The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
June 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Via
The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 28, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
June 28, 2024
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
Via
InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
June 28, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Why Are Altimmune Shares Trading Lower Wednesday?
June 26, 2024
Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer.
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
June 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
June 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 24, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
June 24, 2024
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.
Via
InvestorPlace
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms
June 24, 2024
Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers.
Via
InvestorPlace
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
June 24, 2024
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.
Via
InvestorPlace
Altimmune Stock Is Rising Monday: What's Driving The Action?
June 24, 2024
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes...
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
June 23, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
June 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 21, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
June 21, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
June 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
June 20, 2024
From
Robbins LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
June 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 17, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
June 17, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 14, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
June 13, 2024
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst.
Via
InvestorPlace
3 Stocks Quietly Preparing for a 10X Surge: June Edition
June 12, 2024
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.